Optimization of treatment of cyclic mastalgia in women against psycho-emotional stress
4 affiliations
- 1SI «Ukrainian Center of Maternity and Childhood of the NAMS of Ukraine»; SSI «Center of Innovative Medical Technologies of the NAS of Ukraine», Kyiv , Ukraine
- 2SSI «Center of Innovative Medical Technologies of the NAS of Ukraine»; SI «Ukrainian Center of Motherhood and Childhood of the NAMS of Ukraine», Kyiv, Ukraine
- 3SSI «Center for Innovative Medical Technologies of the NAS of Ukraine», Kyiv, Ukraine
- 4SI “Ukrainian Center of Maternity and Childhood of the NAMS of Ukraine”; Educational and Scientific Centre “Institute of Biology and Medicine” of the Taras Shevchenko National University of Kyiv, Kyiv, Ukraine
Abstract
Objective of the study: To evaluate the effectiveness of combined therapy for cyclic mastalgia using a standardized extract of Vitex agnus castus BNO 1095 compared with magnesium therapy, alongside lifestyle modification and psychological support. Materials and methods. A total of 162 women of reproductive age with cyclic mastalgia were examined and divided into two groups. Group I (n = 79) received a standardized extract of Vitex agnus castus BNO 1095, presented as Agnus castus at a dose of 162 mg in combination with the phytocomponents Саulорhуllum thalictroides D4, Суclamen europaeum D4, Strychnos ignatia D6, Іrіs versicolor D2, Lilium tigrinum D3 as part of the complex herbal medicinal product Mastodinon® (Bionorica, Germany). Group II (n = 83) received magnesium citrate combined with vitamin B6. All participants underwent psychological counseling and lifestyle modification recommendations. The treatment duration was 6 months. Outcomes included pain intensity (NRS), sleep quality (PSQI), anxiety (GAD-7), depressive symptoms (PHQ-9), quality of life (SF-12), hormonal profile (prolactin, progesterone), and breast ultrasound characteristics. Results. In Group I, a statistically significant reduction in mastalgia intensity was observed (NRS: 7.24 ± 3.03 to 1.55 ± 1.47; p < 0.05), whereas Group II showed a less pronounced change (6.67 ± 4.33 to 4.87 ± 2.92). Anxiety levels (GAD-7) decreased significantly in Group I (7.88 ± 0.56 to 4.13 ± 0.61; p < 0.05), while no significant changes were observed in Group II. Sleep quality improved in both groups, but normalization of PSQI was more frequent in Group I. In the Vitex agnus castus group, a reduction in prolactin levels (33.55 ± 5.13 to 15.5 ± 3.12 ng/mL; p < 0.05) and an increase in progesterone levels (6.04 ± 4.01 to 16.56 ± 3.29 nmol/L; p < 0.05) were observed. More pronounced improvements in quality of life and regression of cystic breast changes according to ultrasound data were also noted. Conclusions. Complex therapy with the drug Mastodinon®, which contains a standardized extract Vitex agnus castus BNO 1095, together with lifestyle modification and psychological support is an effective approach for the treatment of cyclic mastalgia. It provides pain reduction, hormonal normalization, improvement of psycho-emotional status, sleep quality, and overall quality of life. The findings support its use as a pathogenetic first-line therapeutic option for cyclic mastalgia.
Related
- Re: Research Article: Emotional Reactivity and Regulation Relate to Surgical Treatment Decision Making Among Newly Diagnosed Women With Breast Cancer
- Spatial distribution and ecological correlates of sexual, physical and emotional violence against adolescent girls and young women in Namibia: a geospatial analysis of a national cross-sectional survey.
- Baseline Response Criterion and Changes in Emotional Bias as Markers of Esketamine Response in Treatment-Resistant Depression
- A Fatal Case of Disseminated Mucormycosis in a Patient Shortly after Starting Treatment against Malignant Lymphoma
- Maternal–Fetal Oncology Intelligence: Self-Evolving Foundation Models and Digital Twin Ecosystems for Precision Cancer Prediction, Treatment Optimization, and Maternal–Fetal Outcome Forecasting
BibTeX
@article{tatarchuk2026optimization,
title = {{Optimization of treatment of cyclic mastalgia in women against psycho-emotional stress}},
author = {T.F. Tatarchuk and N.V. Kosei and V.M. Yakimets and S.I. Regeda and T.M. Tutchenko and K.D. Plaksiieva and R.O. Mnevets},
journal = {Репродуктивная эндокринология},
year = {2026},
month = jul,
doi = {10.18370/2309-4117.2026.84.14-26},
url = {https://doi.org/10.18370/2309-4117.2026.84.14-26},
note = {CC BY},
}
RIS
TY - JOUR
TI - Optimization of treatment of cyclic mastalgia in women against psycho-emotional stress
AU - T.F. Tatarchuk
AU - N.V. Kosei
AU - V.M. Yakimets
AU - S.I. Regeda
AU - T.M. Tutchenko
AU - K.D. Plaksiieva
AU - R.O. Mnevets
PY - 2026
DA - 2026/07/01
JO - Репродуктивная эндокринология
DO - 10.18370/2309-4117.2026.84.14-26
UR - https://doi.org/10.18370/2309-4117.2026.84.14-26
AB - Objective of the study: To evaluate the effectiveness of combined therapy for cyclic mastalgia using a standardized extract of Vitex agnus castus BNO 1095 compared with magnesium therapy, alongside lifestyle modification and psychological support. Materials and methods. A total of 162 women of reproductive age with cyclic mastalgia were examined and divided into two groups. Group I (n = 79) received a standardized extract of Vitex agnus castus BNO 1095, presented as Agnus castus at a dose of 162 mg in combination with the phytocomponents Саulорhуllum thalictroides D4, Суclamen europaeum D4, Strychnos ignatia D6, Іrіs versicolor D2, Lilium tigrinum D3 as part of the complex herbal medicinal product Mastodinon® (Bionorica, Germany). Group II (n = 83) received magnesium citrate combined with vitamin B6. All participants underwent psychological counseling and lifestyle modification recommendations. The treatment duration was 6 months. Outcomes included pain intensity (NRS), sleep quality (PSQI), anxiety (GAD-7), depressive symptoms (PHQ-9), quality of life (SF-12), hormonal profile (prolactin, progesterone), and breast ultrasound characteristics. Results. In Group I, a statistically significant reduction in mastalgia intensity was observed (NRS: 7.24 ± 3.03 to 1.55 ± 1.47; p < 0.05), whereas Group II showed a less pronounced change (6.67 ± 4.33 to 4.87 ± 2.92). Anxiety levels (GAD-7) decreased significantly in Group I (7.88 ± 0.56 to 4.13 ± 0.61; p < 0.05), while no significant changes were observed in Group II. Sleep quality improved in both groups, but normalization of PSQI was more frequent in Group I. In the Vitex agnus castus group, a reduction in prolactin levels (33.55 ± 5.13 to 15.5 ± 3.12 ng/mL; p < 0.05) and an increase in progesterone levels (6.04 ± 4.01 to 16.56 ± 3.29 nmol/L; p < 0.05) were observed. More pronounced improvements in quality of life and regression of cystic breast changes according to ultrasound data were also noted. Conclusions. Complex therapy with the drug Mastodinon®, which contains a standardized extract Vitex agnus castus BNO 1095, together with lifestyle modification and psychological support is an effective approach for the treatment of cyclic mastalgia. It provides pain reduction, hormonal normalization, improvement of psycho-emotional status, sleep quality, and overall quality of life. The findings support its use as a pathogenetic first-line therapeutic option for cyclic mastalgia.
SN - 2309-4117
SN - 2411-1295
ER -